Annals of Oncology最新文献

{"title":"Nivolumab and cabozantinib combination therapy demonstrates sustained efficacy in metastatic renal-cell carcinoma","authors":"Z.A. Yochum , D.A. Braun","doi":"10.1016/j.annonc.2025.10.1238","DOIUrl":"10.1016/j.annonc.2025.10.1238","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 1","pages":"Pages 13-16"},"PeriodicalIF":65.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145426667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO☆","authors":"P. Ciracì ,&nbsp;M.M. Germani ,&nbsp;F. Pietrantonio ,&nbsp;P. Manca ,&nbsp;S. Lonardi ,&nbsp;A. Busico ,&nbsp;F. Bergamo ,&nbsp;V. Burgio ,&nbsp;F. Mannavola ,&nbsp;S. Di Donato ,&nbsp;E. Fenocchio ,&nbsp;F. Palermo ,&nbsp;I. Capone ,&nbsp;M.C. De Grandis ,&nbsp;N. Pella ,&nbsp;M. Scartozzi ,&nbsp;L. Antonuzzo ,&nbsp;A. Passardi ,&nbsp;M. Claravezza ,&nbsp;L. Salvatore ,&nbsp;Claudia Sonaglio","doi":"10.1016/j.annonc.2025.10.002","DOIUrl":"10.1016/j.annonc.2025.10.002","url":null,"abstract":"<div><h3>Background</h3><div>Re-treatment with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies offers a promising approach to extend the continuum of care of patients with <em>RAS</em> and <em>BRAF</em> wild-type (wt) metastatic colorectal cancer (mCRC) with no mutations of resistance in their circulating tumor DNA (ctDNA) at the time of treatment re-exposure.</div></div><div><h3>Patients and methods</h3><div>PARERE (NCT04787341) is an open-label, multicenter, randomized phase II trial investigating the optimal sequencing of panitumumab and regorafenib in chemorefractory <em>RAS</em> and <em>BRAF</em> wt mCRC patients, who previously derived benefit from first-line anti-EGFR-containing regimens, then received at least one intervening anti-EGFR-free line of treatment, and were prospectively selected for the absence of <em>RAS</em> and <em>BRAF</em> mutations in their ctDNA. Eligible patients were randomly assigned 1 : 1 to receive anti-EGFR re-treatment with panitumumab followed by regorafenib after progression (arm A) versus the reverse sequence (arm B). The primary endpoint was overall survival (OS).</div></div><div><h3>Results</h3><div>Between December 2020 and December 2024, 428 patients underwent molecular screening, and 213 with <em>RAS</em>/<em>BRAF</em> ctDNA wt were randomized (arm A/B = 106/107). At a median follow-up of 31.9 months, no difference in terms of OS was observed between treatment arms, with a median OS of 11.7 and 11.6 months in arms B and A, respectively (hazard ratio 1.13, 85% confidence interval 0.90-1.41, <em>P</em> = 0.441). However, re-treatment with panitumumab was associated with higher objective response rate (ORR; first ORR: 16% versus 2%, <em>P</em> = 0.003; second ORR: 18% versus 0%, <em>P</em> = 0.013) and disease control rate (DCR; first DCR: 61% versus 36%, <em>P</em> &lt; 0.001; second DCR: 62% versus 38%, <em>P</em> = 0.003), and longer progression-free survival (PFS; first PFS: 4.2 versus 2.4 months, <em>P</em> = 0.103; second PFS: 3.9 versus 2.7 months, <em>P</em> = 0.019) than regorafenib, regardless of the sequence of the study treatments.</div></div><div><h3>Conclusions</h3><div>Anti-EGFR re-treatment should be regarded as an option in the continuum of care of chemorefractory mCRC patients with <em>RAS</em> and <em>BRAF</em> wt tumors, with no alterations of acquired resistance in their ctDNA.</div></div>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 1","pages":"Pages 79-91"},"PeriodicalIF":65.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145336393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study☆","authors":"K. Fizazi ,&nbsp;N.W. Clarke ,&nbsp;M. De Santis ,&nbsp;H. Uemura ,&nbsp;A.P. Fay ,&nbsp;N. Karadurmus ,&nbsp;M. Kwiatkowski ,&nbsp;C. Alvarez-Fernandez ,&nbsp;S. Jiang ,&nbsp;M. Sotelo ,&nbsp;D. Parslow ,&nbsp;N. Oliveira ,&nbsp;T.G. Kwon ,&nbsp;D. Ye ,&nbsp;S. Boudewijns ,&nbsp;P. Danchaivijitr ,&nbsp;C. Rooney ,&nbsp;C. Gresty ,&nbsp;M. Yeste-Velasco ,&nbsp;J. Logan ,&nbsp;D.J. George","doi":"10.1016/j.annonc.2025.10.004","DOIUrl":"10.1016/j.annonc.2025.10.004","url":null,"abstract":"<div><h3>Background</h3><div>In metastatic hormone-sensitive prostate cancer (mHSPC), phosphatase and tensin homolog (PTEN) deficiency results in phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway activation, providing an independent proliferative drive, which cannot be suppressed by androgen receptor pathway inhibitors (ARPIs), resulting in worse outcomes. Dual inhibition of PI3K/AKT and AR pathways with capivasertib and abiraterone may delay progression and improve disease outcomes.</div></div><div><h3>Patients and methods</h3><div>In CAPItello-281 (NCT04493853), patients with PTEN-deficient mHSPC (diagnostic cut-off: ≥90% viable malignant cells with no specific cytoplasmic PTEN immunohistochemistry staining) received capivasertib or placebo (1 : 1) plus abiraterone, prednisone/prednisolone, and androgen deprivation therapy (ADT). The primary endpoint was investigator-assessed radiographic progression-free survival (rPFS); overall survival (OS) was a key secondary endpoint. <em>Post hoc</em> exploratory subgroups at increasing PTEN cut-off thresholds were also assessed.</div></div><div><h3>Results</h3><div>25.3% (1519/6003) of patients with valid tumor test results had PTEN-deficient tumors. In the randomized PTEN-deficient population, a statistically significant improvement in rPFS was observed with capivasertib plus abiraterone (<em>n</em> = 507, median 33.2 months) versus placebo plus abiraterone [<em>n</em> = 505, 25.7 months; hazard ratio (HR) 0.81, 95% confidence interval (CI) 0.66-0.98, <em>P</em> = 0.034]. <em>Post hoc</em> rPFS analyses for loss of PTEN cut-offs of ≥95%, ≥99%, and 100% showed that the capivasertib plus abiraterone arm performed consistently across cut-offs, but the placebo plus abiraterone arm performed progressively worse as the cut-off for the degree of PTEN loss was increased, resulting in a numerically improved treatment effect. In the overall population studied, the HR for OS (26.4% maturity) was 0.90, 95% CI 0.71-1.15, <em>P</em> = 0.401. The most common adverse events (AEs) for capivasertib plus abiraterone were diarrhea (51.9%; 8.0% placebo plus abiraterone), hyperglycemia (38.0%; 12.9%), and rash (35.4%; 7.0%). Deaths associated with an AE were reported in 36 (7.2%) and 26 (5.2%) patients in the capivasertib plus abiraterone and placebo plus abiraterone arms, respectively.</div></div><div><h3>Conclusions</h3><div>Capivasertib plus abiraterone improves rPFS versus placebo plus abiraterone in PTEN-deficient mHSPC, on a background of ADT, with a 7.5-month improvement in median rPFS. AE profile was consistent with that of the individual agents. Patients with PTEN-deficient mHSPC benefit from dual blockade of the PI3K/AKT and AR pathways with capivasertib plus abiraterone.</div></div>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 1","pages":"Pages 53-68"},"PeriodicalIF":65.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145342556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"16P Dose reduction in neoadjuvant chemotherapy: Outcomes and safety in comorbid elderly-stage breast cancer patients","authors":"X. Wang,&nbsp;Q. Li,&nbsp;J. Wu,&nbsp;L. Zhang,&nbsp;P. Zhang","doi":"10.1016/j.annonc.2025.10.850","DOIUrl":"10.1016/j.annonc.2025.10.850","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 ","pages":"Page S1770"},"PeriodicalIF":65.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145801862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"91P Long-term benefits of ultrasound-guided erector spinae plane block on post-mastectomy pain syndrome in patients undergoing breast surgery: A randomized controlled trial","authors":"P. Godhwal,&nbsp;N. Gupta,&nbsp;B.K. Ratre,&nbsp;S. Mishra,&nbsp;S. Bharti,&nbsp;R. Garg","doi":"10.1016/j.annonc.2025.10.926","DOIUrl":"10.1016/j.annonc.2025.10.926","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 ","pages":"Page S1790"},"PeriodicalIF":65.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145802014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"112P Critical appraisal and assessment of bias among studies evaluating risk prediction models for breast cancer-related lymphatic metastasis: A systematic review","authors":"L. Wang,&nbsp;W. Yu,&nbsp;S. Qiao","doi":"10.1016/j.annonc.2025.10.947","DOIUrl":"10.1016/j.annonc.2025.10.947","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 ","pages":"Page S1795"},"PeriodicalIF":65.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145802016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"6P Association between metabolic dysfunction-associated steatotic liver disease and breast cancer risk in Korean women: A nationwide population-based cohort study","authors":"J.H. Chin ,&nbsp;J.A. Lee ,&nbsp;H.S. Lee ,&nbsp;S.Y. Jeon ,&nbsp;D.R. Kim ,&nbsp;Y.J. Lee ,&nbsp;S.Y. Bae ,&nbsp;W.C. Park ,&nbsp;C.I. Yoon","doi":"10.1016/j.annonc.2025.10.840","DOIUrl":"10.1016/j.annonc.2025.10.840","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 ","pages":"Page S1767"},"PeriodicalIF":65.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145801896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"7P Assessment of overall survival outcomes in elderly patients with ER-positive HER2-negative breast cancer following adjuvant chemotherapy: A population-based cohort study","authors":"W. Lv,&nbsp;G. Yu,&nbsp;P. Wu","doi":"10.1016/j.annonc.2025.10.841","DOIUrl":"10.1016/j.annonc.2025.10.841","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 ","pages":"Page S1767"},"PeriodicalIF":65.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145801897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"8P Exploring whether medical travel enhances survival outcomes of breast cancer: Insights from South Korea’s national health insurance database","authors":"J. Choi ,&nbsp;J. Kim ,&nbsp;Y. Yeo ,&nbsp;H.S. Choi ,&nbsp;E. Ahn ,&nbsp;H.Y. Lee ,&nbsp;J-H. Suh","doi":"10.1016/j.annonc.2025.10.842","DOIUrl":"10.1016/j.annonc.2025.10.842","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 ","pages":"Page S1767"},"PeriodicalIF":65.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145801898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanism-enhanced population science: strengthening population studies through functional insights","authors":"T. Pandya ,&nbsp;Y. Cao ,&nbsp;K. Smith-Byrne ,&nbsp;C. Swanton","doi":"10.1016/j.annonc.2025.08.006","DOIUrl":"10.1016/j.annonc.2025.08.006","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 12","pages":"Pages 1552-1553"},"PeriodicalIF":65.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144939745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}